Author:
Hernandez Diego,Khan Shah Alam,Schlander Michael
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Blank PR, Filipits M, Dubsky P, Gutzwiller F, Lux MP, Brase JC, Weber KE, Rudas M, Greil R, Loibl S (2015) Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients. PharmacoEconomics 33:179–190
2. Erdmann F, Spix C, Katalinic A, Christ M, Folkerts J, Hansmann J, Kranzhöfer K, Kunz B, Manegold K, Penzkofer A (2021) Krebs in Deutschland für 2017/2018
3. Grandt D, Schubert I, Barmer G (2017) Arzneimittelreport 2017, (Berlin, Germany)
4. Gruber EV, Stock S, Stollenwerk B (2012) Breast cancer attributable costs in Germany: a top-down approach based on sickness funds data. PLoS ONE 7(12):e51312
5. Hamada S, Hinotsu S, Ishiguro H, Toi M, Kawakami K (2013) Cross-national comparison of medical costs shared by payers and patients: a study of postmenopausal women with early-stage breast cancer based on assumption case scenarios and reimbursement fees. Breast Care 8(4):282–288